<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00211419</url>
  </required_header>
  <id_info>
    <org_study_id>Double Injection</org_study_id>
    <nct_id>NCT00211419</nct_id>
  </id_info>
  <brief_title>Study of the Combination of Anecortave Acetate and Triamcinolone Acetonide for the Treatment of Exudative Age-Related Macular Degeneration (AMD)</brief_title>
  <official_title>Pilot Study of the Combination of Anecortave Acetate 15mg Delivered by Posterior Juxtascleral Injection and Triamcinolone Acetonide 4mg Delivered by Intravitreal Injection for the Treatment of Exudative Age-Related Macular Degeneration (AMD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Manhattan Eye, Ear &amp; Throat Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Manhattan Eye, Ear &amp; Throat Hospital</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety of combining juxtasclerally administered&#xD;
      anecortave acetate 15 mg with triamcinolone acetate 4 mg administered intravitreally&#xD;
      following photodynamic therapy with verteporfin for the treatment of exudative age-related&#xD;
      macular degeneration (AMD).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Maculopathy, Age-Related</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anecortave Acetate 15 mg</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triamcinolone Acetate 4 mg</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Photodynamic Therapy with Verteporfin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Thermal Laser</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. A male or female with evidence of exudative age-related macular degeneration with&#xD;
             clinical/angiographic/optical coherence tomography (OCT) findings of subfoveal&#xD;
             choroidal neovascularization (CNV) which has not responded to current therapy&#xD;
&#xD;
          2. Baseline best-corrected visual acuity (BCVA) 20/40 to 20/640&#xD;
&#xD;
          3. Patient must be willing and able to comply with the protocol and provide informed&#xD;
             consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients on intravenous, subcutaneous, or anticoagulant therapy (with the exception of&#xD;
             aspirin and antiplatelet therapy) and cannot take a 5 day holiday from therapy prior&#xD;
             to the injection procedure. Note: Patients on oral anticoagulant therapy may be&#xD;
             considered to participate if the physician responsible for monitoring the&#xD;
             anticoagulant therapy agrees that the patient may take a 5 day holiday from therapy&#xD;
             prior to each anecortave injection. The attending doctor must notify the principal&#xD;
             investigator and this notification will be made part of the source documentation.&#xD;
             Anticoagulant therapy may resume either the evening of or the morning after the&#xD;
             injection procedure.&#xD;
&#xD;
          2. Patient with known glaucoma or steroid induced ocular hypertension&#xD;
&#xD;
          3. Intraocular pressures of 21 mmHg or greater at time of entry into the study&#xD;
&#xD;
          4. Patient with significantly compromised visual acuity in the study eye due to&#xD;
             concomitant ocular conditions&#xD;
&#xD;
          5. Patients who have undergone intraocular surgery within last 2 months or capsulotomy&#xD;
             within last month in study eye&#xD;
&#xD;
          6. Patient participating in any other investigational drug study&#xD;
&#xD;
          7. Inability to obtain photographs to document CNV (including difficulty with venous&#xD;
             access)&#xD;
&#xD;
          8. Concomitant oral steroids or topical ophthalmic steroid use&#xD;
&#xD;
          9. Sub-Tenon's injection of steroids within the past 6 months&#xD;
&#xD;
         10. Patient with significant liver disease or uremia&#xD;
&#xD;
         11. Patient with known adverse reaction to indocyanine green, iodine, verteporfin, or&#xD;
             triamcinolone&#xD;
&#xD;
         12. Patient is pregnant or nursing&#xD;
&#xD;
         13. Age less than 50 years old&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jason S Slakter, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Manhattan Eye, Ear &amp; Throat Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Manhattan Eye, Ear &amp; Throat Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2005</verification_date>
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2005</study_first_posted>
  <last_update_submitted>October 23, 2012</last_update_submitted>
  <last_update_submitted_qc>October 23, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 24, 2012</last_update_posted>
  <keyword>Exudative Age-Related Macular Degeneration</keyword>
  <keyword>AMD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Wet Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Anecortave</mesh_term>
    <mesh_term>Verteporfin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

